Final results of the TANIA randomized phase III trial of bevacizumab (BEV) after progression on 1st-line BEV therapy for HER2-negative locally recurrent/metastatic breast cancer (LR/mBC)

被引：0
|
作者：
Vrdoljak, E.
Marschner, N.
Zielinski, C.
Gligorov, J.
Cortes, J.
Puglisi, F.
Aapro, M.
Fallowfield, L.
Fontana, A.
Inbar, M.
Kahan, Z.
Welt, A.
Levy, C.
Brain, E.
Pivot, X.
Putzu, C.
Gonzalez-Martin, A.
Ebel, K.
Easton, V.
von Minckwitz, G.
机构：
[1] Ctr Oncol, Split, Croatia
[2] Outpatient Canc Ctr, Freiburg, Germany
[3] Med Univ Vienna, Ctr Comprehens Canc, Vienna, Austria
[4] CECOG, Vienna, Austria
[5] Hop Tenon, F-75970 Paris, France
[6] Vall dHebron Univ Hosp, Barcelona, Spain
[7] Univ Hosp Udine, Udine, Italy
[8] Clin Genolier, Inst Multidisciplinaire Oncol, Genolier, Switzerland
[9] Univ Sussex, Brighton & Sussex Med Sch, SHORE C, Falmer, England
[10] Univ Hosp Pisa, Ist Toscana Tumori, Pisa, Italy
[11] Tel Aviv Univ, Tel Aviv Sourasky Med Ctr, IL-69978 Tel Aviv, Israel
[12] Univ Szeged, Szeged, Hungary
[13] Univ Duisburg Essen, Univ Hosp Essen, West German Canc Ctr, Essen, Germany
[14] Ctr Francois Baclesse, F-14021 Caen, France
[15] Hop Rene Huguenin, Inst Curie, St Cloud, France
[16] Univ Hosp Jean Minjoz, Besancon, France
[17] Univ Hosp Sassari, Sassari, Italy
[18] MD Anderson Canc Ctr, Madrid, Spain
[19] F Hoffmann La Roche & Co Ltd, CH-4002 Basel, Switzerland
[20] Stamford Consultants AG, Basel, Switzerland
[21] German Breast Grp, Neu Isenburg, Germany
[22] Univ Womens Hosp, Frankfurt, Germany
来源：
CANCER RESEARCH | 2016年 / 76卷
关键词：
D O I：
10.1158/1538-7445.SABCS15-P6-14-01
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P6-14-01
引用
收藏
页数：2
相关论文
共 50 条
  • [21] First results of AVEREL, a randomized phase Ill trial to evaluate bevacizumab (BEV) in combination with trastuzumab (H) plus docetaxel (DOC) as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer (LR/mBC)
    Gianni, L.
    Romieu, G.
    Lichinitser, M.
    Serrano, S.
    Mansutti, M.
    Pivot, X.
    Smirnova, I.
    Moliterni, A.
    Andre, F.
    Chan, A.
    Lipatov, O.
    Chan, S.
    Wardley, A.
    Greil, R.
    Provencher, L.
    Moore, N.
    Prot, S.
    Semiglazov, V.
    CANCER RESEARCH, 2011, 71
  • [22] BIOMARKER (BM) RESULTS FROM THE PHASE III AVEREL TRIAL OF 1ST-LINE BEVACIZUMAB (BV), TRASTUZUMAB (H) plus DOCETAXEL (T) FOR HER2-POSITIVE LOCALLY RECURRENT/METASTATIC BREAST CANCER (LR/MBC)
    Gianni, L.
    Chan, A.
    Mansutti, M.
    Pivot, X.
    Greil, R.
    Provencher, L.
    Prot, S.
    Moore, N.
    Scherer, S. J.
    Pallaud, C.
    ANNALS OF ONCOLOGY, 2012, 23 : 531 - 532
  • [23] Bevacizumab (Bev) combined with either capecitabine (X) or weekly paclitaxel (Pac) as first-line chemotherapy (CT) for HER2-negative, locally recurrent or metastatic breast cancer (LR/MBC): Preliminary safety data from the CECOG phase III TURANDOT trial.
    Lang, I.
    Inbar, M. J.
    Greil, R.
    Steger, G. G.
    Beslija, S.
    Kahan, Z.
    Eniu, A. E.
    Zvirbule, Z.
    Sirbu, D. E.
    Zielinski, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [24] A randomized, placebo-controlled phase II study of AMG 386 plus bevacizumab (Bev) and paclitaxel (P) or AMG 386 plus P as first-line therapy in patients (pts) with HER2-negative, locally recurrent or metastatic breast cancer (LR/MBC)
    Dieras, V.
    Jassem, J.
    Dirix, L. Y.
    Guastalla, J. P.
    Bono, P.
    Hurvitz, S. A.
    Goncalves, A.
    Romieu, G.
    Limentani, S. A.
    Jerusalem, G. H. M.
    Lakshmaiah, K.
    Roche, H. H.
    Sanchez-Rovira, P.
    Pienkowski, T.
    Segui-Palmer, M. A.
    Li, A.
    Sun, Y.
    Pickett-Gies, C. A.
    Wildiers, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [25] Phase II study of bevacizumab (Bev) combined with weekly paclitaxel (wPac) as first-line therapy for Japanese patients (pts) with HER2-negative metastatic breast cancer (MBC).
    Masuda, N.
    Aogi, K.
    Ohno, S.
    Iwata, H.
    Kashiwaba, M.
    Fujiwara, Y.
    Ito, Y.
    Ueno, T.
    Saijo, N.
    Takashima, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [26] Bevacizumab (BV) maintenance therapy significantly delays disease progression (PD) or death compared with placebo (PL) in the AVADO trial (BV plus docetaxel [D] vs D + PL in 1st-line HER2-negative locally recurrent [LR] or metastatic breast cancer [mBC])
    Fumoleau, P.
    Greil, R.
    Rayson, D.
    Mueller, V
    Barni, S.
    Aleknavicius, E.
    Tellez, E.
    Wilson, C.
    Miles, D. W.
    CANCER RESEARCH, 2009, 69 (02) : 104S - 104S
  • [27] Quality of life (QoL) results from the TURANDOT trial comparing two bevacizumab (BEV)-containing regimens as first-line treatment for HER2-negative metastatic breast cancer (mBC)
    Lang, I.
    Inbar, M. J.
    Kahan, Z.
    Greil, R.
    Beslija, S.
    Stemmer, S. M.
    Kaufman, B.
    Ahlers, S.
    Brodowicz, T.
    Zielinski, C.
    CANCER RESEARCH, 2012, 72
  • [28] Phase II trial evaluating the combination of eribulin (E) plus bevacizumab (BEV) as first line chemotherapy in patients with metastatic Her2-negative breast cancer (MBC): a GINECO group study
    Hardy-Bessard, A-C.
    Brocard, F.
    Leheurteur, M.
    Melis, A.
    Dauba, J.
    Lortholary, A.
    You, B.
    Guardiola, E.
    Grenier, J.
    Martin-Babau, J.
    Meunier, J.
    Follana, P.
    Savoye, A-M.
    Mercier-Blas, A.
    Marti, A.
    Despax, R.
    Barbier, N.
    Gane, N.
    Ardisson, P.
    Segura-Djezzar, C.
    ANNALS OF ONCOLOGY, 2016, 27
  • [29] Efficacy of first-line bevacizumab (Bev) combined with weekly paclitaxel (wPac) for HER2-negative metastatic breast cancer (MBC): Results of a Japanese phase II study (n=120)
    Ito, Y.
    Aogi, K.
    Masuda, N.
    Ohno, S.
    Oda, T.
    Iwata, H.
    Kashiwaba, M.
    Fujiwara, Y.
    Kamigaki, S.
    Ueno, T.
    Takashima, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [30] Randomized phase II study of weekly versus every 3 week ixabepilone plus bevacizumab (ixa/bev) versus paclitaxel plus bev (pac/bev) as first-line therapy for metastatic breast cancer (MBC): Final results
    Rugo, H. S.
    Campone, M.
    Amadori, D.
    Wardley, A. M.
    Aldrighetti, D.
    Conte, P. F.
    Liu, D.
    Mudenda, B.
    McHenry, M. B.
    Pivot, X. B.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
12345